Prosecution Insights
Last updated: April 18, 2026
Application No. 18/569,539

PERI-IMPLANTITIS TREATMENT DEVICE AND METHOD FOR ADJUSTING BIOFILM ACTIVITY

Non-Final OA §102§103§112
Filed
Dec 12, 2023
Examiner
CHORBAJI, MONZER R
Art Unit
1799
Tech Center
1700 — Chemical & Materials Engineering
Assignee
National Institute For Materials Science
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
2y 7m
To Grant
97%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allow Rate
915 granted / 1196 resolved
+11.5% vs TC avg
Strong +21% interview lift
Without
With
+20.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
14 currently pending
Career history
1210
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
42.4%
+2.4% vs TC avg
§102
37.1%
-2.9% vs TC avg
§112
13.0%
-27.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1196 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA This is a first action on the merits for this regular application filed on 12/12/2023 Election/Restrictions Claims 1-3 and 9 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected peri-implantities treatment device, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 12/15/25. Applicant’s election without traverse of claims 4-8 and 10-17 in the reply filed on 12/15/25 is acknowledged. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 4-8 and 10-17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In claim 4, lines 2-4, Applicant recites “an electric potential window of higher than a lower limit value of an electric potential window and lower than -0.4 V with respect to a silver/silver chloride electrode reference”. The examiner is unable to determine the metes and bounds of claim 4 because it is not clearly recited if Applicant is referring to the electric potential window for the silver/silver chloride electrode reference? Or to the electric potential window for the conductor having biofilms? It is respectfully requested that claim 4 be rewritten to clearly point to what element the electric potential window represents. For the purpose of this action, the examiner interprets that the electric potential window (electrochemical window) is for a silver/silver electrode reference. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 4, 7-8 and 15 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Ehrensberger et al. (US 2015/0073491 A1). Regarding claim 4, Ehrensberger et al. discloses a biofilm activity adjusting method [0003, 0008, 0035 and 0031], comprising applying, to a conductor having biofilms, an electric potential of higher than a lower limit value of an electric potential window (electrochemical window – EW) and lower than -0.4 V [0008] with respect to a silver/silver chloride electrode reference [0031 and 0052-0053] to inactivate the biofilms. Regarding claim 7, Ehrensberger et al. discloses that the conductor has a current density of lower than 1 µA/cm² ([0068]; -1 mA/cm2 equals -1000 µA/cm²). Regarding claims 8 and 15, Ehrensberger et al. discloses that the biofilms are formed by oral bacteria [0042-0043 and 0043]. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 6, 12, 14 and 17 are rejected under 35 U.S.C. 103 as being unpatentable over Ehrensberger et al. (US 2015/0073491 A1) as applied to claim 4, and further in view of Cui et al. (US 2015/0075992 A1). Regarding claim 6, Ehrensberger et al. discloses that the inactivation is performed in a liquid medium ([0043-004] and Examples 1-8). And Ehrensberger et al. discloses measuring the reductions in the amounts of biofilms, but without expressly stating the method for calculating the biofilms numbers of reductions. Ehrensberger et al. appears silent to disclose the use optical density. Cui et al. discloses a biofouling water sterilization device (Fig.3:300; [0044 and 0046]) by applying a voltage difference between the first porous electrode and the second porous electrode [0007] in order to obtain 99% pathogens inactivation efficiency. Cui et al. goes on to teach using optical density method in order to generate the pathogens growth curves for determining the bactericidal effectiveness [0097-0102]. The claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains to add Cui et al. optical density method to Ehrensberger et al. method in order to generate the pathogens growth curves for determining the bactericidal effectiveness. Regarding claim 12, Ehrensberger et al. discloses that the conductor has a current density of lower than 1 µA/cm² ([0068]; -1 mA/cm2 equals -1000 µA/cm²). Regarding claims 14 and 17, Ehrensberger et al. discloses that the biofilms are formed by oral bacteria [0042-0043 and 0043]. Allowable Subject Matter Claims 5, 10-11, 13 and 16 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The following is a statement of reasons for the indication of allowable subject matter: Regarding claim 5, the primary reason for indicating allowable subject matter is the step of applying a positive electric potential to the conductor to form biofilms. The closest prior art of record (Ehrensberger et al. and Cui et al.), and upon further searches do not teach or fairly suggest adding the step of “applying a positive electric potential to the conductor to form biofilms” to the combined steps of the method claims. Claims 10-11, 13 and 16 are objected merely due to their dependence from claim 5. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MONZER R CHORBAJI whose telephone number is (571)272-1271. The examiner can normally be reached M-F 5:30-12:00 and 6:00-9:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jill J Warden can be reached at (571)272-1267. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MONZER R CHORBAJI/Primary Examiner, Art Unit 1799
Read full office action

Prosecution Timeline

Dec 12, 2023
Application Filed
Apr 04, 2026
Non-Final Rejection — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599905
DROPLET GENERATOR
2y 5m to grant Granted Apr 14, 2026
Patent 12594358
NATURAL METHOD OF REDUCTION AND REMOVAL OF PATHOGENIC AGENTS AND MICROORGANISMS CONTAINED IN SOLIDS
2y 5m to grant Granted Apr 07, 2026
Patent 12595109
DEVICE TO RELEASE WATER AND ANTIMICROBIAL VAPOR INTO AN ENCLOSED OR PARTIALLY ENCLOSED SPACE
2y 5m to grant Granted Apr 07, 2026
Patent 12589174
STERILANT STORAGE DEVICE AND STERILIZATION DEVICE
2y 5m to grant Granted Mar 31, 2026
Patent 12582734
SYSTEM FOR PREVENTING SCALING, REMOVING HYDROGEN PEROXIDE RESIDUES AND RECYCLING WATER IN ASEPTIC FILLING SYSTEMS OF LAMINATED CARTON CONTAINERS
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
97%
With Interview (+20.9%)
2y 7m
Median Time to Grant
Low
PTA Risk
Based on 1196 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month